Topics:

FDA Approves Priority Review of Merck's Zolinza (Vorinostat)

FDA Approves Priority Review of Merck's Zolinza (Vorinostat)

WHITEHOUSE STATION, New Jersey—FDA has granted priority review status to Merck's New Drug Application for Zolinza (vorinostat, also known as suberoylanilide hydroxamic acid or SAHA) for the treatment of advanced cutaneous T-cell lymphoma (CTCL). A pivotal phase IIb trial showed activity in CTCL patients who had failed a median of three previous therapies. Zolinza is potentially the first in a new class of therapies, the histone deacetylase inhibitors.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.